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Received 19 May 2015; accepted 22 June 2015Abstract Background: Diabetes mellitus is a chronic debilitating and non-communicable disease.
It has several long-term outcomes that are associated with various end organ damage, mainly the
heart, blood vessels, eyes, nerves, and kidneys. There are different modalities of treatment of dia-
betes. The recent incretin-based therapies provided an innovative class of drugs including GLP-1
receptor agonists and DPP-4 inhibitors. This review aims to summarize the available evidence of
their effectiveness. Method: This is a narrative review. Several databases were searched. Search
terms used were MeSH and keywords with different combinations of Boolean operators according
to the database but were comparable. Studies included were: randomized controlled trials, cohort
and case-controlled studies, health technology report, meta-analysis, and systematic reviews.
Results were analysed and reported in a narrative style with emphasis on the effectiveness and
adverse effects of various types of incretin based therapies. Results: 17 articles were retrieved as they
fulﬁlled the inclusion criteria. They were heterogeneous in terms of interventions, participants, set-
tings and outcomes. Studies varied in their quality and/or reporting of their ﬁndings conducted in
several settings. There are two types of incretin: Glucose dependent Insulinotropic Peptide (GIP)
and Glucagon-like Peptide 1 (GLP-1). There is no question that incretin-based glucose-lowering
medications have demonstrated to be effective glucose-lowering drugs. They proved an evidence-
based efﬁcacy proﬁle and appear to do so with signiﬁcant effects to stimulate weight loss with min-
imal hypoglycaemia. However, there are few side effects that should not be overlooked when decid-
ing to use such therapies. Conclusion: The ﬁndings of our review presented here, do not prove that
these agents are unsafe, but it does suggest that the burden of evidence now rests with those who
hope to persuade us of their safety. Continuous clinical monitoring and more research are essential
to clarify the actions of GLP-1R agonists and DPP-4 on the normal and diabetic exocrine pancreas.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).l (2015),
2 B. Al Tulaihi, S. AlhabibContents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
2. Review question . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
3. Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4.1. GLP-1 receptors agonists. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4.2. Dipeptidyl peptidase 4 (DPP4) inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
5. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
6. Implications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
Appendix A. search terms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 001. Introduction
Diabetes mellitus is a chronic debilitating and non-
communicable disease characterized by chronic hypergly-
caemia and resulting from a defect in insulin secretion, insulin
action, or both (Alberti and Zimmet, 1998; American Diabetes
Association, 2011). It has several long-term outcomes that are
associated with various end organ damage, mainly the heart,
blood vessels, eyes, nerves, and kidneys (ADA, 2010).
Furthermore, diabetes estimated to cost the government of
Saudi Arabia about $1.87 billion annually (Almalki et al.,
2011).
The number of people with diabetes in 2012 has been esti-
mated to be 381.8 million worldwide with an anticipated
increase of 55% to 591.9 million by 2035 (Guariguata et al.,
2014). In Saudi Arabia, the estimated prevalence of diabetes
in 2011 is 16.2% and estimated to be 20.8% in 2030
(Whiting et al., 2011). There remain large variations in the bur-
den of diabetes across countries and income groups.
Although the number of patients with diabetes that success-
fully achieve target levels of A1C is gradually improving, a
considerable number of subjects continue to fall short of satis-
factory treatment goals, leaving them at high risk for the devel-
opment of diabetes-associated complications (Hoerger et al.,
2008). Suggested initial therapy generally includes lifestyle
management and patient education joined with metformin
therapy. Although metformin is widely accepted as the pre-
ferred medication for the initial treatment of type 2 diabetes
(T2DM), there is still a considerable uncertainty and lack of
consensus regarding the choice of additional agents that need
to be added to metformin to optimize glycaemic control
(Drucker et al., 2010). Other oral hypoglycaemic agents
included also Sulphonylureas such as glipizide, glimepiride,
and glyburide that induce the increased secretion of insulin.
Moreover, insulin, as injection, might be introduced in the
early stage of diabetes, depending on the number of risk fac-
tors the patients may have and the progression/deterioration
of the diabetic stage.
Various drawbacks are associated with the previously dis-
cussed available medications. Amongst the concerns attributed
to the available anti-diabetic medications are that they do not
stop the progressive loss of b cell function, hence, ultimately
they decreased their efﬁcacy and necessitating the need for
exogenous insulin injections (Amori et al., 2007). Most of
the available therapies except metformin are associated withPlease cite this article in press as: Al Tulaihi, B., Alhabib, S. Uncertainties around inc
http://dx.doi.org/10.1016/j.jsps.2015.06.009weight gain and this is disappointing since we know the strong
relationship between obesity and type 2 diabetes (Verspohl,
2009). Studies in Canada show that nearly half of all patients
with T2DM and who are under medication do not attain the
recommended HbA1c levels of 67% (Canadian Diabetes
Association, 2008).
Recent developments in the treatment of diabetes have pro-
vided additional options for the control of diabetes mellitus.
Incretin-based therapies are one of the breakthroughs that
stimulate insulin secretion and reduce glucagon secretion,
resulting in reduction of hepatic glucose production (Perfetti
et al., 2000; Tourrel et al., 2001; Hui et al., 2003). There are
two classes of drugs based on the incretin system: GLP-1
receptor agonist, such as exenatide and liraglutide and DPP-
4 inhibitors that delay endogenous degradation of GLP-1
inhibiting DPP-4 (Triplitt et al., 2007). There are world-wide
uncertainties and controversies regarding the use of such ther-
apies. Therefore, the aim of the review is to summarize an
updated evidence of the effectiveness and safety of incretin-
based agents.
2. Review question
What is the effectiveness of Incetine-based medications and
their side effects in patients with T2DM?
3. Method
This is a narrative review of the evidence from the literature in
order to answer the above-mentioned question.
We searched ﬁve databases including the following: the
Cochrane library, MEDLINE, EMBASE, TRIP, and Science
direct. We also searched databases of ongoing trials
(clinicalTrials.gov/ and controlled-trials.com). Furthermore,
we looked for other potentially eligible trials or ancillary pub-
lications by searching the reference lists of retrieved included
trials, (systematic) reviews, meta-analyses and health technol-
ogy assessment reports.
Search terms used were MeSH and keywords with different
combinations of Boolean operators according to the database
but were comparable (see Appendix A for search terms).
Outcomes measures included: glycaemic control (HA1c), body
mass index (BMI), lipids proﬁles, medications adherence, qual-
ity of life, mental health outcomes, utilization of health ser-
vices, adverse effects, and economic outcomes. Search wasretin-based therapies: A literature review. Saudi Pharmaceutical Journal (2015),
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decided not to have a time limit to the search in order to follow
the history of development of incretin. Studies included were:
randomized controlled trials, cohort and case-controlled stud-
ies, health technology report, meta-analysis, and systematic
reviews. In addition, books and general reviews were retrieved
also providing the history of incretin and their development.
Results were analysed and reported in a narrative style with
emphasis on the effectiveness and adverse effects of various
types of incretin-based therapies.
4. Results
Search revealed 67 hits. Of these, 57 studies were excluded and
17 articles were retrieved as they fulﬁlled the inclusion criteria.
They were heterogeneous in terms of interventions, partici-
pants, settings and outcomes. Studies varied in their quality
and/or reporting of their ﬁndings conducted in several settings
including the following: primary and secondary care. They also
differed in the methods and instruments used to assess the
effectiveness of different types of incretin in controlling
T2DM. Majority of the studies were conducted in Western
countries. All the studies discussed the development and/or
compared the effectiveness of incretin-based drugs with other
hypoglycaemic agents. In all the studies, follow-up of patients
ranged from 8 weeks to 12 months.
This review revealed that there are two types of incretin:
Glucose-dependent Insulinotropic Peptide (GIP) and
Glucagon-like Peptide 1 (GLP-1). GIP was the ﬁrst incretin
to be deﬁned and capable of inhibiting gastrointestinal motility
and the secretion of gastric acid in animals (Brown et al.,
1974). GIP is synthesized by the K cells of the proximal ends
of the jejunum and duodenum in response to high levels of
fat and glucose after intake of food. GIP is easily degraded
by dipeptidyl peptidase 4 (DPP4), which occurs quickly after
its release (Deacon et al., 2000a,b). GIP has its own receptors
(glycoproteins) and acts by exerting insulin-tropic effect that is
primarily induced by glucose (Ross and Dupre, 1978).
Additionally, GIP takes part in the metabolism of fat in cells
of the adipose tissue. There are numerous extra-pancreatic
effects of GIP such as in the gastrointestinal tract, very high
levels of GIP are required to inhibit the secretion of gastric
acid and gastrointestinal motility in humans (Nauck et al.,
1992).
Amongst the molecules that can assign to GLP-1 Receptors
(GLP-1R) and activate it is Exendin-4 (Ex-4), formerly known
as the investigational agent AC2993 and currently as
Exenatide (a synthetic version of Ex-4) (Go¨ke et al., 1993).
The expression of GLP-1R is detected in the heart, gastroin-
testinal tract, nervous system, lung, pituitary glands, skin, C
cells of thyroid, b cells of the pancreas and in the pancreatic
duct (Kim and Egan, 2008). Binding of GIP, GIP-1 and their
receptors leads to the stimulation of glucose-dependent pro-
duction of insulin from the b cells (Lonart et al., 2003).
Furthermore, it has been found that in the brain, GLP-1 is
thought to have a role in the regulation of body weight, food
intake, and appetite (Kim and Egan, 2008).
GLP-1 has numerous extra-pancreatic effects. For example,
in the cardiovascular system, GLP-1 has been observed in vas-
cular smooth muscle cells, endothelial cells, and cardiac myo-
cytes (Ban et al., 2008). They maintained cardiac contractilityPlease cite this article in press as: Al Tulaihi, B., Alhabib, S. Uncertainties around inc
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neuroendocrine and autonomic control through vagal innerva-
tion (Yamamoto et al., 2002). Moreover, GLP-1 has cardio-
protective effects, which assist to protect against heart failure
or ischaemic destruction by increasing myocardial glucose
uptake via increasing production of nitric oxide (Nikolaidis
et al., 2005).
In patients with T2DM, GIP with GLP-1 was found to be
responsible for more than 80% of the incretin effect that fol-
lows after eating of any meal (Freeman, 2009a,b). However,
this effect could be diminished and the receptors desensitized
overtime. Researchers suggested that this was caused by free
fatty acids and chronic hyperglycaemia (Zhou et al., 2007;
Kim and Egan, 2008). Subsequently, wide-ranging research
has been advanced to expand GLP-1 action for longer period
and hence normalization of plasma glucose in type 2 patients
(Knop et al., 2009; Kaur et al., 2014). This resulted in the
development of GLP-1 receptor agonists or DPP-4 enzyme
inhibitors.
4.1. GLP-1 receptors agonists
These agonists are analogues of GLP-1 and they attach to
GLP-1 receptors and stimulate them thereby causing improved
production of insulin, inhibition of glucagon production, and
slow gastric emptying (Ross and Ekoe, 2010). For example;
Exenatide is a synthetic form of exendin-4 (Ex-4) that is iso-
lated from saliva of the Gila monster (Freeman, 2009a,b).
Exenatide was introduced in Europe in May 2007. Exenatide
attaches to GLP-1R with larger afﬁnity than GLP-1 and its
strength in reducing the level of blood glucose is 5000 times
higher than that of native GLP-1 (Parkes et al., 2001). It is
administered subcutaneously twice daily either as monother-
apy or in combination with a thiazolidinedione, sulfonylurea,
or metformin (Freeman, 2009a,b). Liraglutide (Victoza) is
another GLP-1 agonist, which is currently used widely.
Injection of the liraglutide is subcutaneous and it takes
between 10 and 14 h to achieve the peak plasma concentration
(Agersø et al., 2002).
Recently, Exenatide long acting release (LAR) has been
developed, which is the long-acting form of exenatide that is
given once weekly (Knop et al., 2009). The efﬁcacy of exe-
natide LAR was investigated by Kim and colleagues (Kim
et al., 2007) and they found that it causes a 1.4–1.7% reduction
in HbA1c levels. Compared to placebo, it reduces the average
level of glucose in the blood by 39.6 mg/dl and 45 mg/dl when
used at a dose of 0.8 mg and 2.0 mg respectively. Authors high-
lighted that for the patients under the 0.8 mg and 2.0 mg doses
of exenatide LAR, 36% and 86% respectively, they were
shown to achieve HbA1c levels equal to or less than 7%.
Furthermore, the efﬁcacy of exenatide LAR was compared
to that of exenatide and it was found that over time, exenatide
LAR is more effective than exenatide in lowering the level of
HbA1c (Blevins et al., 2011).
The Liraglutide Effect and Action in Diabetes (LEAD)
studies were also conducted examining the efﬁcacy and safety
of the drug using diverse treatment regimens. There were 6
studies comparing different regimen (Buse et al., 2009;
Garber et al., 2009; Marre et al., 2009; Nauck et al., 2009;
Riche et al., 2009; Zinman et al., 2009). In all these trials,
researchers found that when liraglutide is used singly and/orretin-based therapies: A literature review. Saudi Pharmaceutical Journal (2015),
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piride, metformin, rosiglitazone, insulin glargine) to treat
T2DM, there was a dose-dependent reduction in HbA1c levels
and that liraglutide is more effective in lowering the glycaemia
burden and body weight than the comparative existing drugs.
However, the main adverse events were nausea and vomiting,
which observed as a dose-independent effect and fades 4 weeks
after the onset of treatment.
4.2. Dipeptidyl peptidase 4 (DPP4) inhibitors
DPP4 inhibitors exert their effect by inhibiting the dipeptidyl
peptidase 4 enzyme (DPP4), which is responsible for degrading
GLP-1 and GIP. This will improve their availability and hence
reduced levels of blood glucose due to the insulinotropic effect
of GLP-1 (Ross and Ekoe, 2010). Currently, sitagliptin, vilda-
gliptin, saxagliptin, and linagliptin are available as DPP-4 inhi-
bitors. They differ in their bioavailability, half-life, peak
plasma level, and excretion method (Renal or hepatic). For
example; Vildagliptin is the only one that is established to be
effective and well tolerated in type 2 diabetic patients aged
P65 years, compared to other DPP-4 inhibitors, when given
as monotherapy or in combination (Pratley et al., 2007;
Schweizer et al., 2009, 2011). Treating diabetes mellitus in
older population is uniquely challenging. This is due to the risk
of hypoglycaemia associated with using oral anti-diabetic med-
ications or insulin and the risk of marked unawareness of
hypoglycaemia in such population (Chelliah and Burge,
2004; Bremer et al., 2009). Vildagliptin is a highly selective
DPP-4 inhibitor and a promising add-on partner to metformin
(Bosi et al., 2009). This is particularly true in the elderly
patients with some renal impairment. However; Sitagliptin,
for example, needs to be excreted via the kidney (compared
to Vildagliptin that is excreted via the liver) and might not
be suitable for diabetic patients with some impairment of the
renal function (Kim and Egan, 2008). The advantage of
Sitagliptin is its long half-life and therefore, can be used as
once daily, while Vildagliptin should be used on twice daily
basis.
DPP4 inhibitors have several drug interactions. For exam-
ple; the anticoagulant action of warfarin is increased by exe-
natide. Additionally, monoamine oxidase inhibitors may
enhance the hypoglycaemic effect of incretins, beta-blockers
may mask the hypoglycaemic effect of the drugs when given
together, and Sitagliptin has been shown to enhance the
plasma levels of digoxin (Andukuri et al., 2009; Brown et al.,
2009). Corticosteroids, diuretics, and diazoxide may impede
the antidiabetic effects of the incretin-based drugs.
Oestrogens and progestogens may impede the hypoglycaemic
activity of the drugs while testosterone may enhance the hypo-
glycaemic activity (Scheen, 2010).
In a Cochrane systematic review conducted in 2008,
authors found that DPP-4 inhibitors have some theoretical
beneﬁts over existing therapies with oral antidiabetic medica-
tions. Researchers found that DPP4 inhibitors lower HbA1c
levels in a manner that is similar to that of thiazolidinediones,
sulfonylureas, and metformin (Richter et al., 2008). Therefore,
they suggested that DPP-4 inhibitors should presently be lim-
ited to individual patients. Long-term data particularly on car-
diovascular outcomes and safety are urgently needed before
the widespread use of these new drugs. However, in 2012,Please cite this article in press as: Al Tulaihi, B., Alhabib, S. Uncertainties around inc
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been conducted since the inception of DPP-4 inhibitors and
showed that a large body of data supports the long-term safety
of gliptin treatment and refutes an increased risk of infections
including naso-pharyngitis and urinary tract infections
(Goossen and Gra¨ber, 2012). Moreover, several case reports
of pancreatitis with DPP-4 inhibitor treatment have led to
the inclusion of a warning report on all product labels, and
urged an assessment of the pancreatitis risk established on
observational pharmacy claims (Garg et al., 2010; Raschi
et al., 2013) and pooled patient data (Engel et al., 2010).
These post hoc analyses do not support a signiﬁcantly elevated
risk of increasing pancreatitis with gliptin treatment over the
near threefold standard risk that patients with diabetes have
over healthy controls (Gooßen and Gra¨ber, 2012).
5. Discussion
This review showed that incretin-based treatment has several
advantages. There is no question that incretin-based glucose-
lowering medications have demonstrated to be effective
glucose-lowering drugs. GLP-1 receptor agonists prove an
evidence-based efﬁcacy proﬁle and appear to do so with signif-
icant effects to stimulate weight loss with minimal hypogly-
caemia. However, there are few side effects that should not
be overlooked when deciding to use such therapies.
Type 2 diabetes is a complex disease characterized by resis-
tance of the insulin action and eventually a decrease in insulin
secretion. Current therapeutic options for type 2 diabetes such
as sulphonylureas, metformin, thiazolidinedione and a-
glucosidase inhibitors are often failed to reach the recom-
mended targets for glycaemic control. Effectiveness of these
medications usually declines as the disease progresses because
of deterioration of b cell function. Moreover, use of the avail-
able therapies is usually restricted due to inconvenient side
effects such as hypoglycaemia and weight gain. Incretin based
treatments have been developed after understanding of the
incretin physiology and their role in type 2 diabetes. They tar-
geted multiple features of pathophysiology of type 2
diabetes including progressive deterioration of b cell
function as well as high plasma glucagon level. However; there
are some adverse events that should be considered when
treating T2DM patients. Additionally, Incretin therapies are
expensive.
Our review found to be consistent with recent systematic
reviews (only structured abstracts). For example, in a recent
systematic review, researchers found that Liraglutide and exe-
natide once weekly resulted in greater improvement in haemo-
globin A1C and fasting plasma glucose than other incretin
based therapies. In comparison with exenatide twice daily, they
resulted in less effect on post-prandial glucose, comparable
reduction in body weight and produced a good adverse event
proﬁle (CRD, 2015a,b). Another recent systematic review also
ensured that Incretin-based treatments were effective in gly-
caemic control and presented other advantages (e.g., weight
loss with exenatide and liraglutide), which may have an impor-
tant inﬂuence on patient adherence to medication (CRD,
2015a,b). The authors concluded that incretin-based treat-
ments were effective in glycaemic control in patients with
T2DM; they also presented other advantages (like weight loss
with exenatide and liraglutide).retin-based therapies: A literature review. Saudi Pharmaceutical Journal (2015),
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reviewers found that DPP-4 inhibitors were not associated
with a signiﬁcant reduction in cardiovascular death, myocar-
dial infarction, or stroke in patients with type 2 diabetes mel-
litus or impaired glucose intolerance (Morey-Vargas and
Montori, 2014). Moreover, a recent Cochrane meta-analysis
(structured abstract only) revealed that DPP4is and control
treatments did not differ for pancreatitis, sever adverse effects
(SAEs), pancreatic cancer, or total treatment-emergent SAEs
(Morey-Vargas and Montori, 2014). The variations in the
reporting of side effects could be explained by the fact that
the number and duration of trials were insufﬁcient to draw
deﬁnitive conclusions on the adverse events of dipeptidyl
peptidase-4 inhibitors. Other studies however suggest that
incretin-based therapies do not increase one’s risk of pancreati-
tis beyond the expected risk in people with T2DM (Olansky,
2010).
In the above summarized reviews, the majority of the stud-
ies addressed a clear research question, supported by suitable
inclusion criteria. A range of appropriate sources were also
searched to identify studies and attempts were made to ﬁnd
unpublished studies, however; only English language studies
were included so publication bias could not be ruled out.
Appropriate methods were also used to select studies, make
quality assessments and summarize data, which reduced the
chance of reviewer error and bias. The included studies were
not generally of good quality and most were open label, so
the reliability of the ﬁndings was not sufﬁcient. Additionally,
biased documentation of cases and residual confounding in
the observational studies, and cautious selection of partici-
pants into the trials and potential for incomplete or biased
reporting of their results, may explain these differences in their
outcomes. Therefore, these studies cannot fully resolve the
issue of valid occurrence of such adverse effects. In addition,
low event rates and short trial might preclude adequate assess-
ment of the risk for these side effects. These uncertainties mud-
dle the decision to use DPP4-inhibitors. Patients and clinicians
need to consider the beneﬁts that these agents offer (e.g. mod-
est anti-hyperglycaemic effects) and the availability of existing
choices. Hence, it seems wise to avoid DPP4 inhibitors in
patients with risk factors for (alcohol abuse, gallbladder
stones) or a history of acute pancreatitis.
6. Implications
This review has several implications for practice and research.
When incretin-based therapies invented, several studies sug-
gested that they may expose patients with T2DM to some
adverse events. However; more recent clinical studies and sys-
tematic reviews repudiate such prior publications that have
indicated such adverse side effects. This review could be used
as a basis for generating the hypotheses for adequately pow-
ered randomized clinical trials (RCTs) to rigorously and con-
clusively validate or refute the alarming signals from the use
of incretin therapies noted in previous reviews.
The ﬁndings of our review presented here, do not prove that
these agents are unsafe, but it do suggest that the burden of
evidence now rests with those who hope to persuade us of their
safety. Continuous clinical monitoring and more research
are essential to clarify the actions of GLP-1R agonists and
DPP-4 on the normal and diabetic exocrine pancreas.Please cite this article in press as: Al Tulaihi, B., Alhabib, S. Uncertainties around inc
http://dx.doi.org/10.1016/j.jsps.2015.06.009Furthermore, enduring scrutiny and further studies are neces-
sary to clarify the potential implication of reports of pancreatic
injury, including pancreatitis and metaplasia, and rodent
medullary thyroid cancer for human beings treated with
Incretin-based agents. Moreover, at the individual patient
level, clinicians need to base their decision to use incretin-
based agents based on the available best evidence and patients’
choice provided that they are well-informed of the beneﬁts and
risks of such medications.
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